Key points
-
This study was conducted to review the scientific evidence and describe the ocular TEAEs related to pharmacological treatment in patients with multiple sclerosis to provide a theoretical basis and quality literature for ophthalmology specialists, neurologists, and general practitioners, which could help them in making appropriate clinical decisions.
-
Patients under fingolimod and interferon β treatment showed a higher frequency of TEAEs. Alemtuzumab was associated with an autoimmune response that manifested as thyroid eye disease.
-
We recommend physicians to be cautious when treating patients with multiple sclerosis and monitor the ocular symptoms that patients may present. An interdisciplinary approach might be considered to evaluate the patient’s requirements.
Background
Study design
Study selection
Data synthesis and presentation of results
Risk of bias
Results
General description
Characteristics
Author | Year | Study design | Country | Sex | Patients with TEAEs | TEAE | Post-TEAE |
---|---|---|---|---|---|---|---|
ALEMTUZUMAB | |||||||
Tsourdi et al [59] | 2015 | Case series | Germany | Both | 2/5 | Thyroid eye disease | Definitive treatment still discussed / Near-total thyroidectomy and 100 μg levothyroxine per day |
Trinh et al [53] | 2015 | Case report | USA | Female | 1/1 | Thyroid eye disease | Improvement after thyroidectomy and conservative management |
Roos et al [61] | 2018 | Case series | England | Both | 6/162 | Thyroid eye disease | Three patients required systemic immunosuppression and three were managed conservatively |
Tuohy et al [70] | 2014 | Cross-sectional | England | Both | 2/87 | Herpes zoster ophthalmicus | Not reported |
Willis et al [72] | 2016 | Cross-sectional | Wales and England | Both | 1/100 | Conjunctivitis | Not reported |
AMANTADINE | |||||||
Jeng et al [35] | 2008 | Case report | USA | Both | 3/3 | Corneal edema | Improvement after treatment withdrawal in two patients. One patient required penetrating keratoplasty |
Esquenazi [30] | 2009 | Case report | USA | Female | 1/1 | Corneal edema | Improvement after treatment withdrawal and topical prednisolone 1% |
FINGOLIMOD | |||||||
Calabresi et al [9] | 2014 | RCT | Multicentric | Both | 9/1083 | Macular edema | Improvement after treatment withdrawal |
Cohen et al [10] | 2010 | RCT | Multicentric | Both | 6/1292 | Macular edema | Improvement after treatment withdrawal |
Akiyama et al [21] | 2016 | Case report | Japan | Female | 1/1 | Macular edema | Patient refused treatment withdrawal and macular edema resolved |
Chui et al [27] | 2013 | Case report | Australia | Female | 1/1 | Macular edema | Patient refused treatment withdrawal and improvement was observed after treatment with ketorolac and dexamethasone |
Jasani et al [34] | 2017 | Case report | England | Female | 1/1 | Macular edema | Improvement after treatment withdrawal |
Kim et al [37] | 2015 | Case report | USA | Female | 1/1 | Macular edema | Improvement after treatment withdrawal, topical ketorolac and topical prednisolone |
Minuk et al [41] | 2013 | Case report | USA | Female | 1/1 | Macular edema | Patient refused treatment withdrawal and improvement was observed after sub-tenon triamcinolone injection |
Schröder et al [48] | 2015 | Case report | Germany | Female | 1/1 | Macular edema | Treatment was discontinued when ischemic findings appeared |
Thoo et al [52] | 2014 | Case report | Australia | Female | 2/2 | Macular edema | Patient refused treatment withdrawal and improvement was observed after intravitreal triamcinolone injection |
Turaka et al [54] | 2012 | Case report | USA | Male | 1/1 | Macular edema | Improvement after treatment withdrawal |
Cifuentes-Canorea et al [57] | 2019 | Case report | Spain | Female | 1/1 | Macular edema | Improvement after treatment withdrawal and reappearance after restart |
Husmann et al [58] | 2020 | Case report | USA | Female | 1/1 | Macular edema | Treatment was not withdrawn. Macular edema improved with topical nepafenac |
Lapierre et al [63] | 2016 | Cross-sectional | Canada | Both | 11 and 2/2399 | Macular edema and uveitis | Improvement after treatment withdrawal |
Laroni et al [64] | 2016 | Cross-sectional | Italy | Both | 3/825 | Macular edema | 2/3 patients withdrew treatment; one remained with macular edema and one improved. In the last patient, treatment was temporarily interrupted and restarted after improvement |
Ontaneda et al [67] | 2012 | Cross-sectional | USA | Both | 3/317 | Macular edema | Undetermined |
Afshar et al [20] | 2013 | Case series | USA | Both | 3/3 | Cystoid macular edema | Improvement after treatment withdrawal was seen in two patients. One patient continued fingolimod, with improvement after treatment with nepafenac and diflurprednate |
Asensio-Sánchez et al [22] | 2014 | Case report | Spain | Female | 1/1 | Cystoid macular edema | No improvement after treatment withdrawal |
Fan Gaskin et al [33] | 2015 | Case report | Australia | Female | 1/1 | Cystoid macular edema | Improvement after treatment withdrawal, topical diclofenac and topical prednisolone |
Pul et al [44] | 2016 | Case report | Germany | Female | 1/1 | Cystoid macular edema | Improvement after treatment withdrawal and intravitreal ranibizumab injection |
Ueda et al [55] | 2015 | Case report | Japan | Male | 1/1 | Cystoid macular edema and retinal hemorrhages | Macular edema was treated with betamethasone after a 13-week persistence and hemorrhages resolved after 24 weeks |
Zarbin et al [73] | 2013 | Cross-sectional | Multicentric | Both | 19 and 1/2615 | Macular edema and retinal branch vein occlusion | Improvement after treatment withdrawal |
Bhatti et al [24] | 2013 | Case report | USA | Female | 1/1 | Macular hemorrhage | Improvement after treatment withdrawal |
Christopher et al [26] | 2017 | Case report | USA | Female | 1/1 | Conjuctival lymphoma | Improvement after treatment withdrawal and rituximab treatment |
Gallego-Pinazo et al [32] | 2011 | Case report | Spain | Female | 1/1 | Retinal branch vein occlusion | Improvement after treatment withdrawal and intravitreal ranibizumab injection |
Lim et al [76] | 2019 | Cross-Sectional | Multicentric | Both | 27/27,528 | Uveitis complicated with macular edema | One case required glaucoma topical treatment, two cases oral prednisone and the remaining cases received topical steroid preparations |
STEROIDS | |||||||
Saatci et al [45] | 2010 | Case report | Turkey | Male | 1/1 | Acute retinal necrosis | No improvement after treatment withdrawal. Vitrectomy and photocoagulation were required, and retinal detachment occurred after 2 months |
Sheikh et al [49] | 2016 | Case report | USA | Female | 1/1 | Acute retinal necrosis | No improvement after treatment withdrawal |
CTLA4Ig | |||||||
Viglietta et al [17] | 2008 | Non-RCT | USA | Both | 1/20 | Visual field defect | Not reported |
ESTRIOL | |||||||
Voskuhl et al [16] | 2016 | RCT | USA | Both | 4/158 | Visual defects (blurred vision or diplopia) | Not reported |
INTERFERON-β | |||||||
Bakri et al [23] | 2015 | Case report | USA | Female | 1/1 | Intraretinal hemorrhages | Treatment was continued under strict follow-up as the patient was asymptomatic |
Massougnes et al [28] | 2016 | Case report | Switzerland | Male | 2/2 | Retina peripheral bilateral telangiectasiae | Treatment was not withdrawn, and no progression was evidenced |
De Santi et al [29] | 2005 | Case report | Italy | Female | 1/1 | Sicca syndrome | Treatment was not withdrawn and improvement was observed with oral methylprednisolone treatment |
Gaetani et al [31] | 2015 | Case report | Italy | Female | 1/1 | Retinopathy | Improvement after treatment withdrawal |
Jenisch et al [36] | 2012 | Case report | Germany | Female | 1/1 | Branch arterial occlusions and central vein occlusion | Treatment was not withdrawn. Visual acuity improvement was observed after hydroxyethyl- starch and salicylic acid treatment |
Longmuir et al [39] | 2007 | Case report | USA | Male | 1/1 | Retinopathy | Improvement after treatment temporal suspension |
Mallada-Frechín et al [40] | 2005 | Case report | Spain | Female | 1/1 | Retinopathy | Improvement after treatment withdrawal |
Ohira et al [42] | 2009 | Case report | Japan | Female | 1/1 | Retinopathy | Improvement after treatment withdrawal |
Post et al [43] | 2009 | Case report | Canada | Female | 1/1 | Visual field disturbance | Improvement after treatment withdrawal |
Saito et al [46] | 2007 | Case report | Japan | Male | 1/1 | Retinopathy | Improvement after treatment withdrawal |
Sallansonnet-Froment et al [47] | 2009 | Case report | France | Male | 1/1 | Retinopathy | Improvement after treatment withdrawal |
Sommer et al [50] | 2001 | Case report | France | Male | 1/1 | Retinopathy | Improvement after treatment withdrawal |
Spierer et al [51] | 2011 | Case report | Israel | Female | 1/1 | Idiopathic orbital inflammation | Treatment was not withdrawn. Symptoms improved with oral prednisolone |
Williams et al [60] | 2004 | Case series | USA | Both | 3/3 | Neuroretinitis | Not reported |
Makioka et al [66] | 2017 | Cross-sectional | Japan | Both | 1/1476 | Retinopathy | No improvement after treatment withdrawal |
Smith et al [69] | 2015 | Cross-sectional | USA | Both | Incidence rate of 4.04 / 100 patients per year of 8107 adults | Abnormal vision and xerophthalmia | Undetermined |
Tremlett et al [8] | 2008 | Cross-sectional | Canada | Both | 1/888** | Papilledema | Not reported |
Liscić et al [65] | 2004 | Cross-sectional | Croatia | Both | 2/9 | Abnormal visual evoked potentials | No improvement after treatment withdrawal |
Gugliandolo et al [74] | 2018 | Cross-sectional | Italy (three regions: Liguria, Sicily, and Sardinia) | Both | 2/6039 | Eyelid edema and visual field defect | Visual field defect resolved within a day |
Pakdaman et al [18] | 2018 | RCT | Iran | Both | Avonex: 3/89 Cinnovez: 1/93 | Visual disturbance | Not reported |
Comi et al [77] | 2019 | RCT | Multicentric | Both | Ozanimod 1 mg: 1/447 Ozanimod 0.5 mg: 1/451 Interferon-B1a: 1/448 | Macular edema | Not reported |
NATALIZUMAB | |||||||
Boster et al [25] | 2013 | Case report | USA | Male | 1/1 | Progressive Multifocal Leukoencephalopathy by JCV | Patient passed away |
Zecca et al [56] | 2009 | Case report | Switzerland | Male | 1/1 | Ocular toxoplasmosis reactivation | Treatment withdrawal and treatment with pyrimethamine sulfadiazine, prednisolone and folinic acid with lesion reduction |
Holmén et al [62] | 2011 | Cross-sectional | Sweden | Both | 19/85 | Ocular inflammation | Not reported |
Saida et al [13] | 2016 | RCT | Japan | Both | 1/12 | Retinal detachment | Undetermined |
HYPERBARIC OXYGEN | |||||||
Lambrou et al [38] | 1987 | Case report | France | Female | 1/1 | Slow-recovering central bilateral scotoma | Improvement after treatment withdrawal |
RITUXIMAB | |||||||
Rommer et al [68] | 2015 | Cross-sectional | Germany | Both | 1/56 | Ocular inflammation | Not reported |
SIPONIMOD | |||||||
Selmaj et al [14] | 2013 | RCT | Multicentric | Both | 1/297 | Macular edema and optic neuritis | Undetermined |
Kappos et al [12] | 2018 | RCT | Multicentric | Both | 18/1099 | Macular edema | Not reported |
TERIFLUNOMIDE | |||||||
Vermersch et al [15] | 2013 | RCT | Multicentric | Both | Teriflunomide 7 mg: 3/111 | Optic neuritis, macular edema, and optic ischemic neuropathy | Not reported |
TOVAXIN | |||||||
Fox et al [11] | 2012 | RCT | USA | Both | 1/100 | Diplopia | Not reported |
Experimental studies
Observational studies
Adverse events related to each therapy
TEAEs related to alemtuzumab
TEAEs related to amantadine
TEAEs related to fingolimod
TEAEs related to steroids
TEAEs related to CTLA-4 Ig
TEAEs related to estriol
TEAEs related to interferon β
TEAEs related to natalizumab
TEAEs related to hyperbaric oxygen
TEAEs related to rituximab
TEAEs related to siponimod
TEAEs related to teriflunomide
TEAEs related to tovaxin
Discussion
Methodological assessment of TEAEs
Geographical distribution
Pregnancy and hormones in MS
Follow-up recommendations
TEAEs | Referral |
---|---|
Papilledema | Neurologist, priority attention |
Conjunctivitis | Ophthalmologist |
Herpes zoster ophtalmicus | Ophthalmologist and refer depending on the compromise |
Visual disturbance | |
Ocular inflammation | |
Macular edema | Ophthalmologist, if available retina specialist |
Retinal branch vein occlusion | |
Macular hemorrhage | |
Retinal hemorrhages and macular edema | |
Retinopathy | |
Intraretinal hemorrhages | |
Retina peripheral bilateral telangiectasiae | |
Neuroretinitis | |
Retinal detachment | |
Acute retinal necrosis | |
Ocular toxoplasmosis reactivation | Ophthalmologist, if available retina or uvea specialist |
Uveitis | Ophthalmologist, if available uvea specialist |
Abnormal visual evoked potentials | Ophthalmologist, if available neuro-ophthalmologist |
Visual field defect | |
Progressive multifocal leukoencephalopathy by JCV | |
Optic ischemic neuropathy | |
Diplopia | |
Thyroid eye disease | Endocrinologist and ophthalmologist, if available oculoplastics specialist |
Eyelid edema | Ophthalmologist, if available oculoplastics specialist |
Conjuctival lymphoma | |
Idiopathic orbital inflammation | Ophthalmologist, if available ocular surface specialist |
Sjogren syndrome | Rheumatologist and ophthalmologist, if available ocular surface specialist |
Corneal edema | Ophthalmologist, if available cornea specialist |